They also said they had not heard of Mr. Hook, the   shareholder, or Mr. Paxon and said they had little interest in gaining the ear of powerful Washington players. Their goal, they said, is to sell the company to a larger pharmaceutical company. " It wonâ€™t be up to us to seek approval for the drug," Mr. Wilkinson said in the interview, which took place at his hotel on a rundown block in San Francisco, where he was pitching the company to potential buyers at the JPMorgan Health Care Conference. 